Nevada Medicaid spending on GLP-1 drugs

How much did Nevada Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $81.9 million for GLP-1 drugs paid through Nevada Medicaid in 2025, across at least 70,939 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 84 rows of 279, so these figures are floors.

Pharmacies were reimbursed at least $24.9 million for GLP-1 drugs paid through Nevada Medicaid in 2026 (quarter 1 only, as posted so far), across at least 19,396 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 27 rows of 88, so these figures are floors.

By year and ingredient

2020at least $1,439,397No dataat least $3,187,734at least $9,993,307at least $663,590at least $54,991at least $621,941Suppressedat least $15,960,961
2021at least $6,945,085No dataat least $2,866,402at least $17,519,210at least $356,027at least $10,911at least $564,856Suppressedat least $28,262,491
2022at least $12,704,308at least $298,974at least $2,794,439at least $24,235,671at least $296,705Suppressedat least $370,859Suppressedat least $40,700,957
2023at least $18,436,069at least $3,007,654at least $1,224,668at least $24,592,164at least $109,064Suppressedat least $287,381Suppressedat least $47,657,000
2024at least $39,256,994at least $12,212,114at least $655,848at least $10,847,481at least $250,789No dataat least $253,243Suppressedat least $63,476,470
2025at least $51,018,617at least $24,208,669at least $508,870at least $5,962,540at least $31,868No dataat least $137,831Suppressedat least $81,868,395
2026 (Q1)at least $14,001,637at least $9,177,470at least $83,502at least $1,620,007SuppressedNo dataat least $24,828Suppressedat least $24,907,445

By product, 2025

Ozempicat least $47,787,958at least 42,4022 of 26
Rybelsus$2,112,2521,6710 of 24
Wegovyat least $1,118,407at least 87614 of 40
Mounjaroat least $23,829,161at least 19,1767 of 55
Zepboundat least $379,508at least 36419 of 31
Liraglutide (generic name listing)at least $508,870at least 1,79212 of 34
VictozaSuppressedSuppressed10 of 10
Trulicityat least $5,962,540at least 4,4825 of 37
Bydureonat least $31,868at least 283 of 5
ByettaSuppressedSuppressed1 of 1
Exenatide (generic name listing)SuppressedSuppressed3 of 3
Soliquaat least $137,831at least 1483 of 8
XultophySuppressedSuppressed5 of 5

By quarter, 2025

Q1 2025at least $18,694,814at least 16,34921 of 66
Q2 2025at least $21,167,723at least 18,41922 of 66
Q3 2025at least $21,253,651at least 18,32923 of 71
Q4 2025at least $20,752,207at least 17,84218 of 76

By quarter, 2026 (posted so far)

Q1 2026at least $24,907,445at least 19,39627 of 88

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.